ClinicalTrials.gg
RecruitingNCT07780383Updated Sep 24, 2026

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

A Phase 1 interventional study of BMS-986446 in Alzheimer's Disease and Healthy Participants, sponsored by Bristol-Myers Squibb. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Alzheimer Disease by Bristol-Myers Squibb — 12 open to participants now, 13 under way, 10 of them phase 3. Alzheimer Disease · Bristol-Myers Squibb.

Planned enrollment
16th of 26
84 · median 165
Started
2026
with 1 other
Phase 1
12 of 26
1 open now
Primary completion
2027-06
later than 4 of 12 live
Registered
26th of 26
by date

Among the 26 studies in Alzheimer Disease by Bristol-Myers Squibb, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 12 in phase 1, reaches primary completion later than 4 of the 12 other live ones, and was the 26th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

12 of the 26 studies in Alzheimer Disease by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Alzheimer Disease by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration

03

Conditions studied

  • Alzheimer's Disease
  • Healthy Participants

Browse trials for

Keywords

  • Healthy Participants
  • Early Alzheimer's Disease
  • BMS-986446
  • Subcutaneous Administration
  • IV administration
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a of 18.0 to 35.0 kg/m2.
  • For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead , Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.
  • For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.
  • For Part C: Participants must have an (MMSE) score of ≥ 20 to 28 (inclusive).
  • For Part C: Participants must have evidence of positive plasma pTau217.

Exclusion criteria

Exclusion Criteria

  • For Parts A and B: Participants must not have a general history of any gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
  • For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.
  • For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.
  • For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Panel A1: BMS986446

    Drug: BMS-986446

  • Experimental
    Panel A2: BMS986446

    Drug: BMS-986446

  • Experimental
    Panel A3: BMS986446

    Drug: BMS-986446

  • Experimental
    Panel B1: BMS986446

    Drug: BMS-986446

  • Experimental
    Panel B2: BMS986446

    Drug: BMS-986446

  • Experimental
    Panel C1: BMS986446

    Drug: BMS-986446

Interventions

  • Specified dose on specified days

    Also known as: PRX005, Moponetug

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusion

    Time frame: Up to approximately 5 months

  2. Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion

    Time frame: Up to approximately 5 months

  3. Maximum observed concentration (Cmax)

    Time frame: Up to approximately 5 months

  4. Time of maximum observed concentration (Tmax)

    Time frame: Up to approximately 5 months

  5. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to approximately 5 months

  6. Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))

    Time frame: Up to approximately 5 months

  7. AUC(INF)

    Time frame: Up to approximately 5 months

  8. Half-life (T-HALF)

    Time frame: Up to approximately 5 months

  9. Apparent total body clearance in SC administration (CLT/F)

    Time frame: Up to approximately 5 months

  10. Total body clearance in IV infusion (CLT)

    Time frame: Up to approximately 5 months

  11. Apparent volume of distribution of terminal phase in SC administration (Vz/F)

    Time frame: Up to approximately 5 months

  12. Volume of distribution of terminal phase (VZ)

    Time frame: Up to approximately 5 months

Secondary outcomes

  1. Adverse events (AEs)

    Time frame: Up to approximately 5 months

  2. Serious adverse events (SAEs)

    Time frame: Up to approximately 5 months

  3. AEs reported as related to BMS-986446

    Time frame: Up to approximately 5 months

  4. Incidence of anti-drug antibody (ADA)

    Time frame: Up to approximately 5 months

  5. Local tolerance evaluation

    This evaluation will assess pain, itching, burning, pressure, and soreness/tenderness (using a Numeric Rating Scale) at the injection site location.

    Time frame: Up to approximately 5 months

  6. GMR of Panel B1 vs Panel A3 for Cmax

    Time frame: Up to approximately 5 months

  7. GMR of Panel B1 vs Panel A3 for area under the concentration-time curve (AUC)

    Time frame: Up to approximately 5 months

  8. GMR of Panel B2 vs Panel A3 for Cmax

    Time frame: Up to approximately 5 months

  9. GMR of Panel B2 vs Panel A3 for AUC

    Time frame: Up to approximately 5 months

  10. Cmax

    Panel B1, Panel B2, Panel C1

    Time frame: Up to approximately 5 months

  11. Tmax

    Panel B1, Panel B2, Panel C1

    Time frame: Up to approximately 5 months

  12. AUC(0-T)

    Panel B1, Panel B2

    Time frame: Up to approximately 5 months

  13. AUC(0-672)

    Panel B1, Panel B2

    Time frame: Up to approximately 5 months

  14. AUC(INF)

    Panel B1, Panel B2

    Time frame: Up to approximately 5 months

  15. T-HALF

    Panel B1, Panel B2, Panel C1

    Time frame: Up to approximately 5 months

  16. CLT/F

    Panel B1, Panel B2, Panel C1

    Time frame: Up to approximately 5 months

  17. Vz/F

    Panel B1, Panel B2, Panel C1

    Time frame: Up to approximately 5 months

  18. Trough observed plasma concentration (Ctrough)

    Panel C1

    Time frame: Up to approximately 5 months

  19. Concentration at the end of a dosing interval (Ctau)

    Panel C1

    Time frame: Up to approximately 5 months

  20. Area under the concentration-time curve within a dosing interval (AUC(TAU))

    Panel C1

    Time frame: Up to approximately 5 months

07

Study locations

1 of 6 sites recruiting
  • CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
    Anaheim, California 92801, United States
    Recruiting
    • Amina Haggag, Site 0001 · Contact714-774-7777
  • Local Institution - 0003
    Bradenton, Florida 34205, United States
    Not yet recruiting
    • Site 0003 · Contact
  • Local Institution - 0005
    Daytona Beach, Florida 32117, United States
    Not yet recruiting
    • Site 0005 · Contact
  • Local Institution - 0007
    Naples, Florida 34105, United States
    Not yet recruiting
    • Site 0007 · Contact
  • Local Institution - 0006
    The Villages, Florida 32162, United States
    Not yet recruiting
    • Site 0006 · Contact
  • Local Institution - 0004
    Decatur, Georgia 30030, United States
    Not yet recruiting
    • Site 0004 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 9 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 21, 2026
StartActual
Aug 21, 2026
Primary completionEst.
Jun 17, 2027
CompletionEst.
Jun 17, 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07780383
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Aug 21, 2026
Primary completion
Jun 17, 2027 (estimated)
Completion
Jun 17, 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moponetug

Start the discussion